Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward

Current Hematologic Malignancy Reports
Jessica T Leonard, Brandon Hayes-Lattin

Abstract

Outcomes for older adults with acute lymphoblastic leukemia (ALL) remain poor, and allogeneic hematopoietic stem cell transplant (HSCT) remains a potentially curative modality. However, benefits are offset by high rates of non-relapse mortality (NRM) in patients undergoing myeloablative conditioning (MAC) regimens. Reduced intensity conditioning (RIC) regimens can extend this therapy to adults who are unfit for MAC, although at the cost of higher relapse rates. In this review, we discuss evidence to support the usage of RIC regimens, controversies, and potential strategies to improve transplant outcomes going forward. Several novel therapies have recently been approved for the treatment of relapsed ALL and may play an important role in bridging adults with residual disease to RIC transplant. Assessing response to initial therapy via minimal residual disease (MRD) monitoring may determine which patients will derive the most benefit from allogeneic HSCT. Reduced intensity allogeneic HSCT remains a potentially curative therapy that can be offered to older adults however challenges remain. Going forward, MRD testing and novel therapies may help better select which patients should proceed to transplant and assist in getting those pa...Continue Reading

References

Sep 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasDenis Fiere
Oct 13, 2006·Blood·Adele K FieldingUNKNOWN Eastern Cooperative Oncology Group
Jan 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Françoise HuguetHervé Dombret
May 15, 2009·British Journal of Haematology·John M StorringJoseph M Brandwein
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anthony S SteinStephen J Forman
Jan 5, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vincent T HoEdwin P Alyea
Mar 24, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Apr 12, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary EapenRichard E Champlin
May 23, 2015·European Journal of Haematology·Cyril ŠálekUNKNOWN Czech Leukemia Study Group - for Life (CELL)
Apr 26, 2016·The Journal of Clinical Investigation·Cameron J TurtleDavid G Maloney
Jun 14, 2016·The New England Journal of Medicine·Hagop M KantarjianAnjali S Advani
Aug 6, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Federico LussanaAlessandro Rambaldi
Feb 20, 2017·Current Hematologic Malignancy Reports·Rishi Dhawan, David I Marks
Mar 2, 2017·The New England Journal of Medicine·Hagop KantarjianMax S Topp

❮ Previous
Next ❯

Citations

Aug 9, 2019·Journal of Clinical Medicine·Valentina SasUNKNOWN Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation
Mar 28, 2019·Expert Opinion on Investigational Drugs·Marte Karen BrattåsØystein Bruserud
May 30, 2020·Yonsei Medical Journal·Seung Shin LeeUNKNOWN Korean Adult Acute Lymphoblastic Leukemia Working Party

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.